Detailed description of the pharmacological properties and mechanism of action of Bestivan (Vilire)

Belzutifan (Belzutifan, trade name: Welireg) is an oral small molecule drug that is a HIF-2α inhibitor. It specifically targets the abnormally activated hypoxia-inducible factor 2α (HIF-2α) signaling pathway in tumor cells and exerts anti-tumor effects under specific genetic backgrounds. BelzutifanIt has high selectivity and good oral bioavailability. It can be quickly absorbed into the patient's body and exert pharmacological effects. It is suitable for long-term oral treatment.

The core target of bezotivan isHIF-2α protein. HIF-2α can activate the expression of a variety of downstream genes that promote angiogenesis, promote proliferation and inhibit apoptosis in a hypoxic environment, such as VEGF, EPO, etc., thereby promoting tumor growth and metastasis. BelzutifanBy binding to the PAS-B domain in the HIF-2α structure, it cannot bind to ARNT (HIF-β subunit) forms an active complex, thereby blocking HIF-2α-driven gene transcription and inhibiting tumor cell proliferation and angiogenesis.

Compared with traditional targeted therapy drugs, besetifan has the advantages of high selectivity and low toxicity. It can specifically inhibit HIF-2α, but has less impact on HIF-1α or normal cells, so it is less prone to widespread systemic side effects. In addition, Belzutifan’s mechanism of action directly interferes with tumor hypoxic adaptation, allowing it to show significant efficacy in certain genetically related tumors (such as VHL syndrome-related clear cell renal cell carcinoma).

Because bezotivan can target HIF-2α-driven tumor characteristics, it provides a new treatment avenue for patient groups that are difficult to reach with traditional targeted therapies. In clinical trials of VHL related clear cell renal cell carcinoma and other diseases, BelzutifanDemonstrated high objective response rate and good tolerability. In the future, as more HIF-2α-dependent tumors are studied in depth, the drug is expected to be expanded to a wider range of indications and achieve precision treatment.

Reference materials:https://www.drugs.com/